A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102

BJU International

Volumn 101, Issue 1, 2008, Pages 20-25

  Philips, George K ^a,e   Halabi, Susan ^b   Sanford, Ben L ^b   Bajorin, Dean ^c   Small, Eric J ^d  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Hematology/Oncology Unit   (United States)

Author keywords

Carcinoma; Chemotherapy; EGFR; Gefitinib; Urothelial

Indexed keywords

CISPLATIN; GEFITINIB; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAROTID ARTERY THROMBOSIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERURICEMIA; HYPONATREMIA; HYPOTENSION; INFECTION COMPLICATION; KIDNEY FAILURE; LUNG EMBOLISM; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URETER OBSTRUCTION; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER; UROTHELIAL TRACT CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 36849022660     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07226.x     Document Type: Article

References (26)

1. Jemal A, Seigel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003 4 : 489 97
3. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999 17 : 3173 81
4. von MH, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000 18 : 3068 77
5. Soto PH, Cavina R, Latteri F et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002 13 : 1080 6
6. Gandhi V, Du Plunkett WM, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002 20 : 665 73
7. Tempero M, Plunkett W, Ruiz VHV et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003 21 : 3402 8
8. Grunewald R, Du Kantarjian HM, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia. a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992 10 : 406 13
9. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003 46 (Suppl. S85 104
10. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994 69 : 1120 5
11. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990 65 : 1619 25
12. Ravery V, Colombel M, Popov Z et al. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 1995 71 : 196 200
13. Turkeri LN, Erton ML, Cevik I, Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 1998 51 : 645 9
14. Bue P, Wester K, Sjostrom A et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998 76 : 189 93
15. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000 6 : 2053 63
16. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000 6 : 4885 92
17. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004 10 : 4874 84
18. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999 5 : 257 65
19. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004 22 : 777 84
20. Small EJ, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 2003 97 (Suppl. 2090 8
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 16
22. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998 160 : 2021 4
23. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 23 : 18 20
24. Petrylak DP, Faulkner JR, Van Veldhuizen PJ, Mansukhani M, Crawford ED. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 2005 22 : 403
25. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 23 : 5892 9
26. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 : 123 32